An observational study in Neuroendocrine Tumors, NET, sponsored by AHS Cancer Control Alberta. Active, not recruiting at 1 site in Canada. Open to participants aged 14 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by AHS Cancer Control Alberta · Observational
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
676 studies on the registry are indexed under Neuroendocrine Tumors; 169 are open to participants now.
This study's planned enrollment of 115 is close to the median of 115 across 176 observational studies indexed under Neuroendocrine Tumors.
Browse Neuroendocrine Tumors studies →AHS Cancer Control Alberta is the lead sponsor of 182 studies on the registry; 31 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Limited to those subjects with neuroendocrine tumors who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.
The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE
Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.
Time frame: Retrospective data January 2010 - April 30, 2014
Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE
Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics.
Time frame: Retrospective data January 2010 - April 30, 2014
This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AHS Cancer Control Alberta